David Venables

Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom.

Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.

Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom.

Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables.